Does Blue Cross Cover Wegovy? State-by-State Variation in Weight-Loss Drug Coverage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

As of May 2026. Confirm directly with your plan. Coverage varies by state Blue, employer plan, and time. Always confirm with your specific plan administrator.

Key Takeaways

• "Blue Cross" is 33 independent companies. Wegovy coverage policies vary across the state Blues
• Most state Blues cover Wegovy on commercial plans that include weight-loss drug benefits, with PA requiring BMI documentation and comorbidity (for BMI 27 to 29.9)
• The employer plan riding on top of the Blue often determines coverage. Many employer plans exclude weight-loss drugs entirely
• Blue Cross Medicare Advantage covers Wegovy only for the cardiovascular indication after the November 2024 CMS rule
• State insurance departments handle external review for the Blues, with state-specific processes layered on top of the ACA framework

Direct answer

Blue Cross Wegovy coverage depends on which state Blue you have and what your employer plan covers. Most state Blues cover Wegovy with PA for adults meeting BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity, on commercial plans that include weight-loss drug benefits. The specific PA criteria, step-therapy rules, and renewal requirements vary by Blue and by year. Blue Cross Medicare Advantage covers Wegovy only for the cardiovascular indication under the November 2024 CMS rule.

Table of contents

1. The Blue Cross federation and Wegovy coverage variation
2. Anthem Blues vs independent state Blues for Wegovy
3. Common PA elements across the Blues
4. State-by-state coverage notes
5. The employer plan layer: where coverage often gets decided
6. Lifestyle intervention documentation requirements
7. Step therapy with Saxenda on some Blues
8. Renewal criteria: the 5% weight-loss threshold
9. Blue Cross Medicare Advantage and the cardiovascular indication
10. Cost-sharing scenarios on Blue plans
11. Appeals: internal, external, and the state insurance department
12. Out-of-state coverage and BlueCard for Wegovy
13. When coverage fails: alternatives including 503A compounded
14. Contrary view: state-level policy variation as a feature
15. Decision framework
16. FAQ
17. Sources

The Blue Cross federation and Wegovy coverage variation

The Blue Cross Blue Shield Association licenses 33 independent companies to use the Blue brand in defined service areas. Each Blue sets its own commercial formulary and PA rules. Weight-loss drug coverage is one of the policy areas where the Blues have made meaningfully different choices.

Anthem owns the Blue plans in 14 states (California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin). The Anthem Blues coordinate on some policy but file separately by state. Other major Blues include BCBS Michigan, BCBS Texas (an HCSC plan), Florida Blue, BCBS Massachusetts, Highmark Blues (Pennsylvania, Delaware, West Virginia, New York), and Independence Blue Cross (Pennsylvania).

Anthem Blues vs independent state Blues for Wegovy

Anthem Blues use CarelonRx (formerly IngenioRx) as the PBM for most plans. CarelonRx PA criteria for Wegovy are similar across Anthem states but file separately. The PA generally requires BMI 30+ or BMI 27+ with a comorbidity, documented lifestyle intervention, and age 18+ for the adult indication.

Independent Blues use various PBMs:

• BCBS Michigan: Express Scripts on some plans
• BCBS Texas (HCSC): Prime Therapeutics
• Florida Blue: Prime Therapeutics
• Highmark: Highmark Pharmacy Services (in-house PBM)
• BCBS Massachusetts: in-house or contracted PBM depending on plan

The PBM matters for PA workflow and appeal logistics but not for the underlying coverage decision, which the Blue sets.

Common PA elements across the Blues

The Wegovy PA pattern is consistent in shape across the Blues:

• BMI documented with measurement date
• BMI 30+ for the obesity indication, or BMI 27+ with comorbidity for the overweight indication
• Comorbidity diagnoses with supporting evidence
• Age 18 or older (or pediatric criteria for ages 12 to 17)
• Lifestyle intervention documentation
• Sometimes step therapy with Saxenda or another agent
• Quantity limit (one pen per 28 days at maintenance)

Initial approval is typically 6 months. Renewal requires documented weight loss, usually 5% from baseline.

State-by-state coverage notes

These are summaries. The current PA form on each Blue's website is authoritative.

Anthem Blue Cross California: covers Wegovy with PA on plans that include weight-loss drug coverage. BMI documentation, comorbidity (for BMI 27 to 29.9), and lifestyle intervention required. Step therapy with Saxenda applies on some plans.

BCBS Michigan: covers Wegovy with PA. BMI and comorbidity criteria align with FDA labeling. Documentation of weight-loss attempts required.

BCBS Texas (HCSC): covers Wegovy with PA on plans that include the benefit. Many large Texas employer plans exclude weight-loss drugs; check the SBC.

Florida Blue: covers Wegovy with PA. Initial approval 6 months. Renewal requires 5% weight loss.

Highmark Blues: cover Wegovy with PA. Step therapy with Saxenda on some plans. Lifestyle intervention documentation required.

BCBS Massachusetts: covers Wegovy with PA. Massachusetts state law affects some plan designs.

BCBS FEP plans cover Wegovy with PA on Standard and Basic Options. FEP Blue Focus has tighter rules.

The employer plan layer: where coverage often gets decided

State Blues service many self-funded employer plans. Under ERISA, the employer sets the benefit design. Weight-loss drug coverage is frequently the variable element.

Common employer plan configurations on Blue plans:

• Standard Blue PA with weight-loss drug coverage included (the most common)
• Standard Blue PA with weight-loss drug coverage excluded entirely
• Modified PA with additional documentation requirements
• Coverage only for Wegovy's cardiovascular indication
• Coverage tied to enrollment in an employer-sponsored weight-management program

The Summary of Benefits and Coverage and Evidence of Coverage are authoritative. Read them.

Lifestyle intervention documentation requirements

Blue PAs require lifestyle intervention documentation. The accepted forms vary by Blue:

• Commercial weight-loss program enrollment records (WeightWatchers, Noom, Jenny Craig)
• Dietitian or nutritionist visit records
• Behavioral health visit records addressing eating patterns
• Chart notes from primary care visits where weight management was specifically addressed
• Records of an employer-sponsored or insurer-sponsored wellness program

The duration requirement varies: some Blues require 3 to 6 months prior; others accept concurrent engagement.

Step therapy with Saxenda on some Blues

Some Blue plans require a Saxenda trial before Wegovy. The clinical rationale is that Saxenda (liraglutide) is in the same drug class and lower cost. Step-therapy exceptions are available with documented clinical reasoning.

Common step-therapy exception grounds:

• Prior Saxenda trial with inadequate response or intolerance
• Contraindication to Saxenda
• Patient-specific clinical reason (the daily injection of Saxenda vs the weekly injection of Wegovy in patients with adherence concerns)

Renewal criteria: the 5% weight-loss threshold

Most Blue plans renew Wegovy coverage based on documented weight loss of at least 5% from baseline within 6 months. The criterion is consistent with FDA labeling for continuation of obesity pharmacotherapy.

Renewal documentation includes:

• Baseline weight at start of therapy
• Current weight
• Percentage weight loss
• Continued lifestyle engagement
• Continued tolerability

Patients on slow titration who have not reached maintenance dose at 6 months may have the renewal review take dose trajectory into account.

Blue Cross Medicare Advantage and the cardiovascular indication

Blue Cross Medicare Advantage plans cover Wegovy only for the cardiovascular indication, following the November 2024 CMS final rule. The criteria:

• Documented established cardiovascular disease (prior MI, stroke, peripheral artery disease, coronary revascularization)
• BMI 27 or higher
• Prescription written for the cardiovascular indication
• Standard Part D PA met

The Part D $2,000 annual OOP cap applies. The Novo Nordisk manufacturer card is not available to Medicare beneficiaries.

Cost-sharing scenarios on Blue plans

Scenario	Approximate monthly cost
State Blue commercial, Wegovy covered, with manufacturer card	$0 to $25 (terms vary)
State Blue commercial, Wegovy covered, no card	$25 to $200 copay
State Blue commercial, Wegovy not covered, with card	~$650 cash-pay (eligibility)
State Blue commercial, Wegovy not covered, no card	$1,300 to $1,450 cash
BCBS Medicare Advantage, CV indication	$50 to $150, up to $2,000 OOP cap

Appeals: internal, external, and the state insurance department

Blue Cross appeals follow a defined process:

1. Internal appeal filed with the Blue within the deadline on the denial letter (60 to 180 days, varies by Blue)
2. If denied, external review under ACA Section 2719
3. External review through the Blue's vendor or your state insurance department
4. Decision binding on the Blue if overturned

Several states (New York, California, Texas, Florida, Michigan) run their own external review processes. The Blue's denial letter directs you to the correct path.

Out-of-state coverage and BlueCard for Wegovy

BlueCard allows you to access in-network care when traveling outside your home Blue's service area. For Wegovy, your home Blue's formulary and PA rules control. You can fill at any BCBS-participating pharmacy in any state if your home Blue has approved the PA.

If you move permanently, your coverage shifts to the Blue at your new address. A new PA is typically required. Tier placement, step therapy, and renewal criteria may change.

When coverage fails: alternatives including 503A compounded

If your Blue will not cover Wegovy and the manufacturer card or patient assistance program cannot bridge the cost, 503A compounded semaglutide via telehealth is a path worth understanding.

503A compounded semaglutide is the same active molecule as Wegovy but is not FDA-approved and not equivalent. The product is prepared individually for each patient by a state-licensed 503A pharmacy. FormBlends works with state-licensed 503A pharmacies and licensed clinicians for clinically eligible patients.

The compounded path is cash-pay. It is not billable to any Blue or any commercial insurer.

Contrary view: state-level policy variation as a feature

The Blue federation produces a patchwork of Wegovy coverage policies that frustrates members. The defense rests on local control. Drug pricing pressure, employer mix, state regulations, and population health needs differ across states. A national rule that worked in Florida might not fit California; one that fit Michigan might not work in Texas.

The federation does allow national coordination on data and broad policy. The BCBS Association runs national programs (BlueCard, the FEP). The Blues compete on local execution. For Wegovy, that means coverage policies look similar in outline and differ in detail. Members in two states can experience meaningfully different access. That is a feature for state-level policy autonomy and a friction for members who relocate.

Decision framework

Find your Blue first. Read your member ID card. Identify the home Blue and the employer plan.

Read the SBC. Confirm whether your employer plan covers weight-loss drugs.

If covered: file the PA with BMI documentation, comorbidity diagnoses, and lifestyle intervention history. Address each PA criterion specifically.

If denied: read the denial letter carefully. Address the specific reason in the appeal.

If excluded: internal appeal will not overturn. Pursue manufacturer card, patient assistance, or 503A.

If on Medicare Advantage: CV indication only.

FAQ

Does Blue Cross cover Wegovy? Depends on your specific Blue and employer plan. Most Blues cover with PA when the benefit is included.

Why does it vary? 33 independent licensees, plus employer plan layering.

What's the BMI threshold? 30+, or 27+ with comorbidity.

How long is initial approval? 6 months typically.

Renewal criterion? 5% weight loss from baseline.

Does BCBS Medicare cover Wegovy? Only for the cardiovascular indication.

How do I appeal? Internal with the Blue, then external review through your state.

What about BlueCard travel? Home Blue's PA controls; can fill at any participating BCBS pharmacy.

Sources

1. Blue Cross Blue Shield Association. National federation overview.
2. Anthem (Elevance Health). Weight-loss drug PA criteria. 2026.
3. BCBS Michigan, BCBS Texas (HCSC), Florida Blue, Highmark Blues formularies. 2026.
4. U.S. Food and Drug Administration. Wegovy prescribing information.
5. Lincoff AM, et al. SELECT cardiovascular outcomes. NEJM. 2023;389:2221-2232.
6. Wilding JPH, et al. STEP 1. NEJM. 2021;384:989-1002.
7. Centers for Medicare and Medicaid Services. Final rule on Part D for cardiovascular indications. November 2024.
8. Social Security Act, Section 1860D-2(e)(2). Part D weight-loss exclusion.
9. Affordable Care Act, Section 2719 external review.
10. State insurance departments (NY, CA, TX, FL, MI) external review processes.
11. Endocrine Society obesity pharmacotherapy guideline.
12. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians through telehealth. We do not adjudicate insurance benefits. Information about Blue Cross plans reflects publicly available materials as of May 2026 and may change at plan renewal.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy on an individual prescription basis. It is not FDA-approved and is not equivalent to brand-name Wegovy. Decisions should involve a prescribing clinician.

Results Disclaimer. Coverage and weight-loss outcomes vary based on plan rules, clinical situation, and individual response. Patterns described here do not predict any specific case.

Trademark Notice. Blue Cross and Blue Shield are registered service marks of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Elevance Health. Wegovy, Saxenda, and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is independent.